We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
8.00 | 2.63% | 312.00 | 296.00 | 303.00 | 312.00 | 312.00 | 312.00 | 5,059 | 10:35:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
UK Analysts Meeting and Webcast Scheduled Today at 9:00 a.m. BST
U.S. Conference Call Scheduled Today at 9:00 a.m. EDT
Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market, today announces its unaudited financial results for the six months ended June 30, 2016.
Simon To, Chairman of Chi-Med, said: “Chi-Med has once again made very considerable progress at both the operating and strategic levels.
All aspects of our Innovation Platform’s risk-balanced, innovative drug pipeline have moved forward, including progress in aligning with U.S. and European regulatory authorities in end-of-Phase II meetings on savolitinib and completing enrollment of our first Phase III study on fruquintinib. We have also made great progress in the clinic on sulfatinib, epitinib, HMPL-523, HMPL-689 and theliatinib, all of which are also potential global first-in-class or best-in-class drug candidates.
Once again, our Commercial Platform has generated increased cash flows helping fund our Innovation Platform activities as well as providing a first-class marketing and distribution channel in China for our drug candidates, if they are approved. Our partnerships with major global pharmaceutical companies, created when the global scope of our drug candidates began to emerge, continue to allow us to broaden development plans and represent important global marketing and distribution resources. In the first half, we completed our Nasdaq listing, which broadened our exposure to U.S. specialist investors and strengthened our cash position.
The progress of our drug pipeline and strong cash position, resulting from our increased commercial profits and recent Nasdaq listing, have enabled us to renegotiate our collaboration agreement with AstraZeneca to take a greater share in the potential long-term economic value of savolitinib in return for increasing our investment in savolitinib’s development. We believe this benefits both Chi-Med and AstraZeneca as it allows us to accelerate and broaden savolitinib’s late-stage development in multiple oncology indications.
Our pragmatic approach to finance and risk management has enabled us to build our drug pipeline over a dozen years. We now have multiple shots at success with four pivotal studies underway today, and three more likely to initiate by H1 2017, on a diversified group of drug candidates. The results of these pivotal studies will emerge during 2017-2019, and we believe that if they prove successful, substantial benefits can be created for patients and shareholders alike. Consequently, we view the future with great confidence.”
FINANCIAL HIGHLIGHTS:
Our consolidated financial results are reported under U.S. generally accepted accounting principles (“U.S. GAAP”) and in U.S. dollar currency unless otherwise stated. We also conduct our business through three non-consolidated joint ventures, which are accounted for under the equity accounting method as non-consolidated entities in our consolidated financial statements. Within this announcement, we refer to certain financial results reported by such non-consolidated joint ventures, which are based on figures reported in their respective consolidated financial statements prepared pursuant to International Financial Reporting Standards (as issued by the International Accounting Standards Board). Unless otherwise indicated, references to “subsidiaries” refer to our consolidated subsidiaries and joint ventures (excluding non-consolidated joint ventures).
Group Results
Innovation Platform – a broad, risk-balanced, global oncology/immunology pipeline.
Commercial Platform – a deeply established, cash-generative, pharmaceutical business in China – a commercialization framework for our Innovation Platform candidate drugs.
2016 FINANCIAL GUIDANCE: We provide full year 2016 financial guidance, as detailed below:
Group Level:
Innovation Platform:
Commercial Platform:
KEY H1 2016 OPERATIONAL HIGHLIGHTS:
Innovation Platform: Multiple opportunities for success: four pivotal Phase III studies underway and three more fully funded and expected to begin by H1 2017. Each is expected to read-out over the next three years.
1. Kidney cancer:
a. Completed end-of-Phase II meetings with U.S. Food & Drug Administration (“FDA”) and European Medicines Agency (“EMA”); alignment on plans for global savolitinib monotherapy Phase III study in c-Met-driven papillary renal cell carcinoma (“PRCC”) patients.
b. Initiated global Phase Ib dose finding study of savolitinib in combination with anti-programmed death-1 receptor ligand (“PD-L1”) antibody, durvalumab, in clear cell renal cell carcinoma (“ccRCC”) patients.
2. Non-small cell lung cancer (“NSCLC”):
a. Initiated global Phase IIb study of savolitinib in combination with Tagrisso® (osimertinib) in second-line NSCLC patients with epidermal growth factor receptor (“EGFR”) mutations who have failed first-line EGFR tyrosine kinase inhibitor (“TKI”) therapy and harbor c-Met gene amplification. This triggered a $10 million milestone from AstraZeneca to Chi-Med in June 2016.
b. Initiated or continued four further Phase Ib/II studies in first-, second- and third-line NSCLC patients, including (i) as a monotherapy in NSCLC patients with c-Met mutations that result in Exon 14 skipping; (ii) as a monotherapy in pulmonary sarcomatoid carcinoma (“PSC”) patients with mutations that result in Exon 14 skipping; (iii) as a combination therapy with Iressa® (gefitinib) in NSCLC patients with EGFR mutations and who have failed first-line EGFR TKI therapy; and (iv) as a combination therapy with Tagrisso® in third-line NSCLC patients who have failed Tagrisso® therapy.
3. Gastric Cancer:
a. Proof-of-concept studies of savolitinib as a monotherapy in gastric cancer patients with c-Met gene amplification are ongoing in South Korea and China; promising response data, was published by Dr. Jeeyun Lee of Samsung Medical Center in April 2016 at the American Association of Cancer Research meeting.
b. A Phase Ib dose finding study of savolitinib in combination with Taxol® (docetaxel) in gastric cancer patients with c-Met over-expression is ongoing in South Korea.
1. Colorectal cancer (third-line or above): Completed enrollment of a Phase III study, named FRESCO, to test fruquintinib as a monotherapy among third-line metastatic colorectal cancer patients in China; top-line Phase III data expected to be reported in early 2017; plan to submit the China NDA, subject to positive FRESCO outcome, by mid-2017;
2. NSCLC (third-line): Began enrolling a Phase III study, named FALUCA, to test fruquintinib in third-line NSCLC patients in China, in late 2015 – now over 30 clinical centers are operational; expect to complete enrollment in H1 2017; top-line Phase III data expected to be reported in late 2017; plan to submit China NDA, subject to positive FALUCA outcome, during H1 2018.
3. Gastric cancer (second-line): Completed dose finding stage of fruquintinib Phase Ib study in combination with Taxotere® (paclitaxel). Continue to enroll patients in Phase Ib expansion stage.
4. NSCLC (first-line): Planning underway to start Phase Ib dose finding study of fruquintinib in combination with Iressa® in first-line EGFR-mutant NSCLC patients in China in late 2016.
5. Production facility in Suzhou, China, operational and ready to support fruquintinib’s potential commercial launch.
1. NET (first-line):
a. Completed enrollment of a Phase II study of sulfatinib in 81 broad-spectrum NET patients in China; median Progression Free Survival (“PFS”) not yet reached; now enrolling two Phase III studies, named SANET-p (in pancreatic NET patients) and SANET-ep (in extra-pancreatic NET patients), with primary endpoint median PFS; Phase III top-line data expected in 2018.
b. Initiated U.S. Phase I dose confirmation study in Caucasian patients – currently in 200mg cohort and closing in on China 300mg Phase III dose; expected to complete in H2 2016.
2. Thyroid cancer: Initiated Phase II proof-of-concept study in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer in China.
3. Biliary tract cancer: Planning underway to start a Phase II study in China in late 2016.
1. Hematological cancer: Granted China FDA Phase I to Phase III clinical trial application clearance in H1 2016 – target to start China Phase I dose escalation in patients with hematologic malignancies in H2 2016; Australia Phase I dose escalation currently in second dose cohort (200mg) and expected to complete in H1 2017; U.S. hematological malignancy Investigational New Drug (“IND”) application submitted in June 2016.
2. Immunology: Australia Phase I study completed with no evidence of the hypertension/gastrointestinal toxicities encountered by the first-generation Syk inhibitor (fostamatinib); U.S. immunology IND application submitted in H1 2016 – U.S. FDA feedback received, now preparing to submit additional data; planning global rheumatoid arthritis Phase II study for 2017.
1. NSCLC with brain metastasis: Phase Ib study in NSCLC patients with brain metastasis ongoing; granted China FDA Phase II/III clinical trial application clearance granted in July 2016; target to initiate pivotal registration study in H1 2017.
2. Glioblastoma: Planning underway to start a Phase II study in glioblastoma, a primary brain cancer with EGFR gene amplification, in early 2017.
Hematological cancer: Initiated Phase I study in healthy volunteers in Australia in H1 2016, now in fifth cohort and expected to complete Phase I dose escalation in H2 2016; plan to start Phase I dose escalation in patients with hematologic malignancies in Australia in H1 2017.
Esophageal cancer/Head and Neck: Phase I dose escalation study ongoing in China; target to start Phase Ib proof-of-concept studies by the end of 2016.
Commercial Platform: Continued strong growth in cash flow and profit – representing a solid and stable financial base that underpins a significant portion of Chi-Med’s current market value.
1. She Xiang Bao Xin (“SXBX”) pill – our most important commercial product, is a prescription vasodilator proprietary to our joint venture: Accounted for approximately 12% of China’s over $1.5 billion botanical coronary artery disease prescription drug market, full patent protection through 2029; H1 2016 sales up 16% to $110.1 million (H1 2015: $94.9m); SXBX pill represents 87% of the sales of SHPL, our joint venture, which contributed 91% of our $16.3 million (H1 2015: $12.1m) consolidated Prescription Drugs operating profit in H1 2016.
2. Seroquel® – prescription antipsychotic under exclusive commercial license from AstraZeneca within China: Accounted for approximately 5% of China’s antipsychotic prescription drug and 46% of the generic quetiapine market; Seroquel® is the only extended release (“XR”) quetiapine formulation approved in China; H1 2016 sales up 282% to $17.2 million (H1 2015: $4.5m); 2016 is the first full year of Seroquel® commercialization under Chi-Med.
EXPECTED MAJOR NEAR-TERM CATALYSTS: We target to publish data on four drug candidates in five Phase Ib-III studies before the end of Q1 2017, including:
We target to initiate pivotal registration trials on two further drug candidates before the end of H1 2017, including:
POST PERIOD EVENT: Amendment of Co-Development Agreement with AstraZeneca on Savolitinib global development plan:
In order to accelerate savolitinib’s global development, as announced yesterday, Chi-Med and AstraZeneca agreed to amend the 2011 global licensing, co-development and commercialization agreement regarding savolitinib. Under the amendment, Chi-Med will contribute up to $50 million, spread primarily over three years, to the joint-development costs of the global pivotal Phase III study in c-Met-driven PRCC. Subject to approval in the PRCC indication, Chi-Med will receive a 5 percentage point increase in the global (excluding China) tiered royalty rate payable on savolitinib sales across all indications, thereby increasing the tiered royalty to 14% to 18%. After total aggregate sales of savolitinib have reached $5 billion, the royalty will step down over a two year period, to an ongoing royalty rate of 10.5% to 14.5%. All other provisions of the 2011 Agreement will remain unchanged.
Conference Call and Webcast Information:
An analyst presentation and webcast will be held today at 9:00 a.m. BST (4:00 p.m. HKT) at Citigate Dewe Rogerson, Third Floor, 3 London Wall Buildings, London, EC2M 5SY. Investors may participate in the call or access a live video webcast of the call via the Company’s website at www.chi-med.com/investors/event-information/. A conference call for U.S. investors will also be held today at 9:00 a.m. EDT. To participate in the US call, please dial +1-212-999-6659. For all dial-in numbers please use conference ID “Chi-Med”.
About Chi-Med
Chi-Med is an innovative China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 0001). For more information, please visit: www.chi-med.com.
References
Unless the context requires otherwise, references in this announcement to the “Group,” the “Company,” “Chi-Med,” “Chi-Med Group,” “we,” “us” and “our” refer to Chi-Med and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “pipeline,” “could,” “potential,” “believe,” “first-in-class,” “best-in-class,” “designed to,” “objective,” “guidance,” “pursue,” or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such drug candidates will achieve any particular revenue levels. In particular, management’s expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to meet our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the inability of a drug candidate to meet the primary or secondary endpoint of a study; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or gain commercial acceptance after obtaining regulatory approval; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; and general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries and uncertainties regarding future global exchange rates. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med is providing the information in this announcement as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
In addition, this announcement contains statistical data and estimates that we obtained from industry publications and reports generated by third-party market research firms, including Frost & Sullivan, an independent market research firm, and publicly available data. All patient population, market size and market share estimates are based on Frost & Sullivan research, unless otherwise noted. Although we believe that the publications, reports and surveys are reliable, we have not independently verified the data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.
Inside Information
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Ends
Hutchison China MediTech Limited
Condensed Consolidated Balance Sheets
(In US$’000)
June 30,December 31,
20162015
(unaudited) Assets Current assets Cash and cash equivalents 75,952 31,941 Short-term investments 46,587 - Accounts receivable – third parties 35,851 33,346 Accounts receivable – related parties 2,678 1,869 Other receivables, prepayments and deposits 2,522 3,258 Amounts due from related parties 1,045 9,293 Inventories 7,923 9,555 Deferred tax assets 215 250 Total current assets 172,773 89,512 Property, plant and equipment, net 8,773 8,507 Leasehold land 1,291 1,343 Goodwill 3,282 3,332 Other intangible asset 523 571 Long-term prepayment 1,964 2,132 Deferred costs for initial public offering in the United States - 4,446 Investments in equity investees 134,237 119,756 Total assets 322,843 229,599 Liabilities and shareholders’ equity Current liabilities Accounts payable – third parties 24,147 20,565 Accounts payable – a related party 4,547 3,521 Other payables, accruals and advance receipts 23,679 26,177 Deferred revenue 906 1,171 Amounts due to related parties 8,551 6,243 Short-term bank borrowings 15,077 23,077 Deferred tax liabilities 2,400 308 Total current liabilities 79,307 81,062 Deferred tax liabilities 1,571 3,415 Long-term bank borrowings 26,799 26,768 Deferred revenue 2,903 3,498 Deferred income 2,578 2,132 Other non-current liabilities 10,519 10,447 Total liabilities 123,677 127,322 Commitments and contingencies Company’s shareholders’ equity Ordinary share; US$1.00 par value; 75,000,000 shares authorized; 60,649,342 and 56,533,118 shares issued at June 30, 2016 and December 31, 2015 60,649 56,533 Additional paid-in capital 206,985 113,848 Accumulated losses (91,510) (92,040) Accumulated other comprehensive income 2,327 5,015 Total Company’s shareholders’ equity 178,451 83,356 Non-controlling interests 20,715 18,921 Total shareholders’ equity 199,166 102,277 Total liabilities and shareholders’ equity 322,843 229,599Hutchison China MediTech Limited
Condensed Consolidated Statements of Operations
(Unaudited, in US$’000, except share and per share data)
Six Months EndedJune 30,
2016 2015 Revenues Sales of goods – third parties 76,861 50,786 Sales of goods – related parties 5,398 4,772 Revenue from license and collaboration agreements – third parties 18,088 23,248 Revenue from research and development services – third parties 355 1,317 Revenue from research and development services – related parties 3,815 2,362 Total revenues 104,517 82,485 Operating expenses Costs of sales of goods – third parties (66,445) (46,448) Costs of sales of goods – related parties (4,041) (3,494) Research and development expenses (31,184) (21,260) Selling expenses (8,846) (3,799) Administrative expenses (9,958) (7,516) Total operating expense (120,474) (82,517) Loss from operations (15,957) (32) Other income/(expense) Interest income 189 318 Other income 138 278 Interest expenses (811) (707) Other expenses (329) - Total other expense (813) (111) Loss before income taxes and equity in earnings of equity investees (16,770) (143) Income tax expense (1,687) (1,161) Equity in earnings of equity investees, net of tax 21,251 19,368 Net income 2,794 18,064 Less: Net income attributable to non-controlling interests (2,257) (2,115) Net income attributable to the Company 537 15,949 Accretion on redeemable non-controlling interests - (42,015) Net income/(loss) attributable to ordinary shareholders of the Company 537 (26,066) Earnings/(losses) per share attributable to ordinary shareholders of the Company – basic (US$ per share) 0.01 (0.49) Earnings/(losses) per share attributable to ordinary shareholders of the Company – diluted (US$ per share) 0.01 (0.49) Number of shares used in per share calculation – basic 58,822,425 53,172,325 Number of shares used in per share calculation – diluted 59,126,085 53,172,325Hutchison China MediTech Limited
Condensed Consolidated Statements of Comprehensive (Loss)/Income
(Unaudited, in US$’000)
Six Months EndedJune 30,
2016 2015 Net income 2,794 18,064 Other comprehensive (loss)/income: Foreign currency translation (loss)/income (3,151) 5 Total comprehensive (loss)/income (357) 18,069Less: Comprehensive income attributable to non-controlling
interests
(1,794) (2,122)Total comprehensive (loss)/income attributable to ordinary
shareholders of the Company
(2,151) 15,947Hutchison China MediTech Limited
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(Unaudited, in US$’000, except share data in ’000)
Ordinary
Number
SharesAmount
AdditionalPaid-in
Capital
AccumulatedLosses
AccumulatedOther
Comprehensive
Income
TotalCompany’s
Shareholders’
Equity
Non-controlling
Interests
TotalEquity
As of January 1, 2015 53,076 53,076 76,256 (100,051) 9,870 39,151 17,764 56,915 Net income - - - 15,949 - 15,949 2,115 18,064 Issuance of ordinary shares in relation to exercise of options 224 224 1,024 - - 1,248 -
1,248
Share-based compensation: share options - - 106 - - 106 - 106 Transfer between reserve - - 24 (24) - - - - Foreign currency translation adjustments - - - - (2) (2) 7 5 Dilution of interests in a subsidiary in relation to exercise of options of a subsidiary - - - 2 - 2 - 2 Accretion to redemption value of redeemable non-controlling interests - - (42,015) - - (42,015) - (42,015) As of June 30, 2015 53,300 53,300 35,395 (84,124) 9,868 14,439 19,886 34,325 As of January 1, 2016 56,533 56,533 113,848 (92,040) 5,015 83,356 18,921 102,277 Net income - - - 537 - 537 2,257 2,794 New ordinary shares issued 4,080 4,080 106,080 - - 110,160 - 110,160 Issuance of ordinary shares in relation to exercise of options 36 36 109 - - 145 - 145 Issuance costs - - (14,227) - - (14,227) - (14,227) Share-based compensation: Share options - - 1,088 - - 1,088 - 1,088 Long-term incentive plan - - 684 - - 684 - 684 - - 1,772 - - 1,772 - 1,772 Transfer between reserve - - 7 (7) - - - - Foreign currency translation adjustments - - - - (2,688) (2,688) (463) (3,151) Long-term incentive plan: treasury shares held by Trustee - - (604) - - (604) - (604) As of June 30, 2016 60,649 60,649 206,985 (91,510) 2,327 178,451 20,715 199,166Hutchison China MediTech Limited
Condensed Consolidated Statements of Cash Flows
(Unaudited, in US$’000)
Six Months EndedJune 30,
2016 2015 Operating activities Net income 2,794 18,064 Adjustments to reconcile net income to net cash generated from operating activities Amortisation of finance costs 31 31 Depreciation and amortization 1,133 896 Loss on retirement of property plant and equipment 5 - Inventories written off - 9 Decrease in provision for excess and obsolete inventories due to sales of inventories (20) (6) Allowance for doubtful accounts 55 51 Share-based compensation expense – share options 1,160 275 Share-based compensation expense – long-term incentive plan 786 - Equity in earnings of equity investees (21,251) (19,368) Dividend received from equity investees 15,917 6,410 Unrealized currency translation losses/(gains) 791 (87) Income taxes 76 746 Changes in operating assets and liabilities Accounts receivable – third parties (2,560) (8,150) Accounts receivable – related parties (809) (1,071) Other receivables, prepayments and deposits 736 208 Amounts due from related parties 1,248 (1,284) Inventories 1,652 (2,607) Long-term prepayment 168 (2,404) Accounts payable – third parties 3,582 466 Accounts payable – related parties 1,026 3,108 Other payables, accruals and advanced receipts 641 326 Deferred revenue (860) (721) Deferred income 446 2,404 Amounts due to related parties 2,308 3,147 Net cash generated from operating activities 9,055 443 Investing activities Purchases of property, plant and equipment (1,570) (1,446) Deposit (in)/out short-term investments (46,587) 12,179 Investment in an equity investee (5,000) - Net cash (used in)/generated from investing activities (53,157) 10,733 Financing activities Proceeds from issuance of ordinary shares 110,305 1,248 Proceeds from exercise of share options of a subsidiary - 2 Payment of issuance costs (12,721) - Purchase of treasury shares (604) - Proceeds from bank borrowings 5,128 - Repayment of bank borrowings (13,128) (2,564) Net cash generated from/(used in) financing activities 88,980 (1,314)Net increase in cash and cash equivalents 44,878 9,862 Effect of exchange rate changes on cash and cash equivalents (867) 22 44,011 9,884 Cash and cash equivalents Cash and cash equivalents at beginning of period 31,941 38,946 Cash and cash equivalents at end of period 75,952 48,830
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801006417/en/
Chi-MedInvestor EnquiriesChristian Hogg, CEO+852 2121 8200orInternational Media EnquiriesAnthony Carlisle, Citigate Dewe Rogerson+44 7973 611 888 (Mobile)anthony.carlisle@cdrconsultancy.co.ukorU.S. Based Media EnquiriesBrad Miles, BMC Communications+1 (917) 570 7340 (Mobile)bmiles@bmccommunications.comorSusan Duffy, BMC Communications+1 (917) 499 8887 (Mobile)sduffy@bmccommunications.comorInvestor RelationsBrian Korb, The Trout Group+1 (917) 653 5122 (Mobile)bkorb@troutgroup.comorDavid Dible, Citigate Dewe Rogerson+44 7967 566 919 (Mobile)david.dible@citigatedr.co.ukorPanmure Gordon (UK) LimitedRichard Gray / Andrew Potts+44 (20) 7886 2500
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions